LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Primary care faecal calprotectin testing in children with suspected inflammatory bowel disease: a diagnostic accuracy study.

    Walker, Gareth J / Chanchlani, Neil / Thomas, Amanda / Lin, Simeng / Moore, Lucy / Heerasing, Neel M / Hendy, Peter / Abdelrahim, Mohamed / Mole, Sean / Perry, Mandy H / Mcdonald, Timothy J / Bewshea, Claire M / Hart, James W / Russell, Richard K / Ahmad, Tariq / Goodhand, James R / Kennedy, Nicholas A

    Archives of disease in childhood

    2020  Volume 105, Issue 10, Page(s) 957–963

    Abstract: Objective: To determine the diagnostic accuracy of calprotectin to diagnose inflammatory bowel disease (IBD) in children in whom general practitioners (GPs) suspected IBD.: Design: Prospective observational cohort study of a new calprotectin-based ... ...

    Abstract Objective: To determine the diagnostic accuracy of calprotectin to diagnose inflammatory bowel disease (IBD) in children in whom general practitioners (GPs) suspected IBD.
    Design: Prospective observational cohort study of a new calprotectin-based primary care referral pathway.
    Setting: 48 GP practices and gastroenterology secondary care services at the Royal Devon and Exeter NHS Foundation Trust in the South-West of England, UK.
    Patients: 195 children aged between 4 and 18 years referred on the pathway between January 2014 and August 2017 for investigation of gastrointestinal symptoms were included.
    Interventions: Primary-care-driven faecal calprotectin testing. Primary and secondary care records over 12 months from the point of calprotectin testing were used as the reference standard.
    Main outcome measures: Diagnostic accuracy of calprotectin testing to detect IBD.
    Results: 7% (13/195) tested patients were diagnosed with IBD. Using our prespecified cut-off of 100 µg/g, calprotectin had a diagnostic accuracy of 91% (95% CI 86% to 95%) with a sensitivity for distinguishing IBD from non-IBD of 100% (95% CI 75% to 100%), a specificity of 91% (95% CI 85% to 94%), a positive predictive value of 43% (95% CI 25% to 63%) and a negative predictive value of 100% (95% CI 98% to 100%). Calprotectin testing had no effect on the time to diagnosis, but a negative test contributed to saved referrals and was associated with fewer diagnostic tests in secondary care.
    Conclusions: Calprotectin testing of children with suspected IBD in primary care accurately distinguishes IBD from a functional gut disorder, reduces secondary care referrals and associated diagnostic healthcare utilisation.
    MeSH term(s) Adolescent ; Biomarkers/metabolism ; Child ; Child, Preschool ; Cohort Studies ; Feces/chemistry ; Female ; Humans ; Inflammatory Bowel Diseases/diagnosis ; Leukocyte L1 Antigen Complex/metabolism ; Male ; Predictive Value of Tests ; Referral and Consultation/statistics & numerical data ; Sensitivity and Specificity
    Chemical Substances Biomarkers ; Leukocyte L1 Antigen Complex
    Language English
    Publishing date 2020-05-18
    Publishing country England
    Document type Journal Article ; Observational Study
    ZDB-ID 524-1
    ISSN 1468-2044 ; 0003-9888 ; 1359-2998
    ISSN (online) 1468-2044
    ISSN 0003-9888 ; 1359-2998
    DOI 10.1136/archdischild-2019-317823
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines

    Kennedy, Nicholas A / Lin, Simeng / Goodhand, James R / Chanchlani, Neil / Hamilton, Benjamin / Bewshea, Claire / Nice, Rachel / Chee, Desmond / Cummings, JR Fraser / Fraser, Aileen / Irving, Peter M / Kamperidis, Nikolaos / Kok, Klaartje B / Lamb, Christropher A / MacDonald, Jonathan / Mehta, Shameer J / Pollok, Richard CG / Raine, Tim / Smith, Philip J /
    Verma, Ajay M / Mcdonald, Timothy J / Sebastian, Shaji / Lees, Charlie / Powell, Nick / Ahmad, Tariq / CLARITY IBD Contributors

    medRxiv

    Abstract: Background Delayed second-dose SARS-CoV-2 vaccination trades maximal effectiveness for a lower level of immunity across more of the population. We investigated whether patients with inflammatory bowel disease treated with infliximab have attenuated ... ...

    Abstract Background Delayed second-dose SARS-CoV-2 vaccination trades maximal effectiveness for a lower level of immunity across more of the population. We investigated whether patients with inflammatory bowel disease treated with infliximab have attenuated serological responses to a single-dose of a SARS-CoV-2 vaccine. Methods Antibody responses and seroconversion rates in infliximab-treated patients (n=865) were compared to a cohort treated with vedolizumab (n=428), a gut-selective anti-integrin a4B7 monoclonal antibody. Our primary outcome was anti-SARS-CoV-2 spike (S) antibody concentrations 3-10 weeks after vaccination in patients without evidence of prior infection. Secondary outcomes were seroconversion rates, and antibody responses following past infection or a second dose of the BNT162b2 vaccine. Findings Geometric mean [SD] anti-SARS-CoV-2 antibody concentrations were lower in patients treated with infliximab than vedolizumab, following BNT162b2 (6.0 U/mL [5.9] vs 28.8 U/mL [5.4] P<0.0001) and ChAdOx1 nCoV-19 (4.7 U/mL [4.9]) vs 13.8 U/mL [5.9] P<0.0001) vaccines. In our multivariable models, antibody concentrations were lower in infliximab- compared to vedolizumab-treated patients who received the BNT162b2 (fold change [FC] 0.29 [95% CI 0.21, 0.40], p<0.0001) and ChAdOx1 nCoV-19 (FC 0.39 [95% CI 0.30, 0.51], p<0.0001) vaccines. In both models, age > 59 years, immunomodulator use, Crohn9s disease, and smoking were associated with lower, whilst non-white ethnicity was associated with higher, anti-SARS-CoV-2 antibody concentrations. Seroconversion rates after a single-dose of either vaccine were higher in patients with prior SARS-CoV-2 infection and after two doses of BNT162b2 vaccine. Interpretation Infliximab is associated with attenuated immunogenicity to a single-dose of the BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines. Vaccination after SARS-CoV-2 infection, or a second dose of vaccine, led to seroconversion in most patients. Delayed second dosing should be avoided in patients treated with infliximab. Funding Royal Devon and Exeter and Hull University Hospital Foundation NHS Trusts. Unrestricted educational grants: F. Hoffmann-La Roche AG (Switzerland), Biogen GmbH (Switzerland), Celltrion Healthcare (South Korea) and Galapagos NV (Belgium).
    Keywords covid19
    Language English
    Publishing date 2021-03-29
    Publisher Cold Spring Harbor Laboratory Press
    Document type Article ; Online
    DOI 10.1101/2021.03.25.21254335
    Database COVID19

    Kategorien

To top